161 related articles for article (PubMed ID: 16966264)
1. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
3. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
[TBL] [Abstract][Full Text] [Related]
6. [Divergence Analysis of Hepatitis Virus Infection between Aggressive and Indolent B Cell Non-Hodgkin's Lymphoma].
Xiong WJ; Li H; Liu HM; Yi SH; Li ZJ; Lu R; Liu W; Zou DH; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1754-1758. PubMed ID: 28024489
[TBL] [Abstract][Full Text] [Related]
7. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
8. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use.
Herold M; Sacchi S; Hieke K
Haematologica; 2002 Jul; 87(7):719-29; discussion 729. PubMed ID: 12091123
[TBL] [Abstract][Full Text] [Related]
9. Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study).
Stienen JJ; Hermens RP; Wennekes L; van de Schans SA; Dekker HM; Blijlevens NM; van der Maazen RW; Adang EM; van Krieken JH; Ottevanger PB
Implement Sci; 2013 Jul; 8():77. PubMed ID: 23837833
[TBL] [Abstract][Full Text] [Related]
10. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
11. Utilization and cost of health care services associated with primary malignant brain tumors in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Thornton DE; Crown WH
J Neurooncol; 2007 Jan; 81(1):61-5. PubMed ID: 16773215
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
13. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
14. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
15. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
19. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting.
Bernardo M; Crawford P; Hertel J; Sholer C; Xu X; Goss T; Kewalramani R; Globe D
J Manag Care Pharm; 2006; 12(9):714-25. PubMed ID: 17249904
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
